Remote levodopa challenge test in Parkinson's disease: Feasibility, reliability, validity and economic value
European Journal of Neurology · 2024
DOI: 10.1111/ene.16423 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2024. Verfasst von Zhitong Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Centre for Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Parkinson Disease, Levodopa, Feasibility Studies, Antiparkinson Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission, Guangci Innovative Technology Launch Program, Science and Technology Innovation Plan Of Shanghai Science and Technology Commission.
Abstract (Originalsprache)
Background and purpose The aim was to demonstrate the feasibility, reliability and validity of an in‐home remote levodopa challenge test (LCT), as delivered through an online platform, for patients with Parkinson's disease (PwPD).
Methods
Patients with Parkinson's disease eligible for deep brain stimulation surgery screening were enrolled. Participants sequentially received an in‐home remote LCT and an in‐hospital standard LCT (separated by 2.71 weeks). A modified Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III omitting rigidity and postural stability items was used in the remote LCT. The reliability of the remote LCT was evaluated using the intraclass correlation coefficient and the concurrent validity was evaluated using the Pearson's correlation coefficient r between the levodopa responsiveness of the remote and standard LCT.
Results
Out of 106 PwPD screened, 80 (75.5%) completed both the remote and standard LCT. There was a good reliability (intraclass correlation coefficient 0.81, 95% confidence interval 0.69–0.88) and a strong correlation ( r = 0.84, 95% confidence interval 0.77–0.90) between the levodopa responsiveness of the remote and standard LCT. The mean cost for PwPD was estimated to be reduced by 91% by using the remote LCT.
Conclusion
The remote LCT is feasible, reliable and valid and may reduce healthcare‐related costs for PwPD and their caregivers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Centre for Functional Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- HUST-GYENNO CNS Intelligent Digital Medicine Technology Centre, Wuhan, China.
- Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Clinical Neuroscience Centre, Ruijin Hospital LuWan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Zhitong Zeng, Zhengyu Lin, Chencheng Zhang
Förderung
- Shanghai Municipal Health Commission
- Guangci Innovative Technology Launch Program
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
Zitieren
APA
Zeng, Z., Lin, Z., Chen, Z., Wan, X., Zhou, H., Zhang, C., Sun, B., Ren, K., & Li, D. (2024). Remote levodopa challenge test in Parkinson's disease: Feasibility, reliability, validity and economic value. European Journal of Neurology. https://doi.org/10.1111/ene.16423
Vancouver
Zeng Z, Lin Z, Chen Z, Wan X, Zhou H, Zhang C, et al. Remote levodopa challenge test in Parkinson's disease: Feasibility, reliability, validity and economic value. European Journal of Neurology. 2024. doi:10.1111/ene.16423
BibTeX
@article{Zeng2024,
author = {Zeng, Zhitong and Lin, Zhengyu and Chen, Zhonglue and Wan, Xiaonan and Zhou, Haiyan and Zhang, Chencheng and Sun, Bomin and Ren, Kang and Li, Dianyou},
title = {Remote levodopa challenge test in Parkinson's disease: Feasibility, reliability, validity and economic value},
journal = {European Journal of Neurology},
year = {2024},
doi = {10.1111/ene.16423}
}
EUVIMED